EGFR and non-small cell lung carcinoma: In the FLAURA study, a randomized and double-blind phase III clinical study that aimed to assess the efficacy and safety of osimertinib in previously untreated advanced NSCLC with EGFR mutations, it was found that, compared with first-generation EGFR-TKIs, first-line treatment with osimertinib significantly prolonged mPFS by 8.7 months, and extended mOS to 38.6 months, thereby reducing the mortality risk for patients by 20%[23].